




FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-16212	National Phase Filing of PCT Serial No. PCT/US04/028811
	First Applicant BALES, Kelly Renee, et al	
	Filing Date US Nat'l Entry (if applicable)	Group 1633



U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No. 1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US 2002/0107213A1	Aug. 8, 2002	Verlinden, et al	
	AB				
	AC				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO 97/16458	05/09/1997	Kos Holdings, Inc.		
	BB	WO 00/23587	04/27/2000	Introgene B.V.		
	BC					

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	BAEKELANDT, et al., "Characterization of Lentiviral Vector-Mediated Gene Transfer in Adult Mouse Brain", Human Gene Therapy, May 2002, pgs. 841-853, Vol. 13, No. (7)	
	CB	BOSCH, et al., "Reversal of Pathology in the Entire Brain of Mucopolysaccharidosis Type VII Mice after Lentivirus-Mediated Gene Transfer", Human Gene Therapy, May 2000, pgs. 1139-1150, Vol. 11, No. (8)	

Examiner Signature 	Date Considered 1/6/08
---	---------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified)		Atty. Docket No. X-16212	National Phase Filing of PCT Serial No. PCT/US04/028811
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		First Applicant BALES, Kelly Renee, et al	
		Filing Date US Nat'l Entry (if applicable)	Group 1633
MM	CC	DODART, et al., "Lentivirus-Mediated Expression of Human Apolipoprotein E Alters Brain A β Burden in an Isoform-Dependent Manner in PDAPP Mice", Society for Neuroscience Abstract viewer and Itinerary Planner, Vol. 2003, Abstract No. 730.2	
	CD	DODART, et al., "Gene delivery of human apolipoprotein E alters brain A β burden in a mouse model of Alzheimer's disease", PNAS (USA), Jan. 25, 2005, pgs. 1211-1216, Vol. 102, No. (4)	
	CE	NALDINI, et al., "Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector", PNAS (USA), Oct. 1996, pgs. 11382-11388, Vol. 93, No. (21)	
	CF	OYAMA, et al., "Apolipoprotein E genotype, Alzheimer's pathologies and related gene expression in the aged population", Molecular Brain Research, Mar. 1995, pgs. 92-98, Vol. 29, No. (1)	
	CG	ROYSTON, et al., "Apolipoprotein E ϵ 2 allele promotes longevity and protects patients with Down's syndrome from dementia", Neuroreport, Dec. 1994, pgs. 2583-2585, Vol. 5, No. (18)	
	CH	SJOGREN, et al., "Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype", J Neural Transm, April 2001, pgs. 451-458, Vol. 108, No. (4)	
	CI	TALBOT, et al., "Protection against Alzheimer's disease with apoE ϵ 2", The Lancet, June 4, 1994, pgs. 1432-1433, Vol. 343, No. (8910)	

Examiner Signature	MMannich	Date Considered	1/6/08
-----------------------	----------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.
Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.